Dan Bradbury is a veteran biopharmaceutical executive with more than four decades of experience leading biotechnology companies, advancing innovative medicines, and building long-term shareholder value. 

He is the Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded biotechnology company based in La Jolla, California, where he previously served as Executive Chairman until 2025 and Chief Executive Officer until 2020. He is also the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm based in La Jolla, California. 

Earlier in his career, Dan was President, Chief Executive Officer, and Director of Amylin Pharmaceuticals in San Diego. During his 18-year tenure, Amylin launched multiple first-in-class medicines, including the first once-weekly therapy for diabetes, and joined the Nasdaq-100 prior to its acquisition by Bristol-Myers Squibb in 2012. Before joining Amylin, Dan spent ten years at SmithKline Beecham Pharmaceuticals in a range of marketing and sales leadership roles. 

Dan serves on the boards of directors of Castle Biosciences, Inc. (NASDAQ: CSTL), Equillium, Inc. (NASDAQ: EQ), and Vivani Medical, Inc. (NASDAQ: VANI), as well as several private companies and philanthropic organizations. He holds a Bachelor of Pharmacy from the University of Nottingham and a Diploma in Management Studies from the University of West London in the United Kingdom.  

At NeuraClick, he provides strategic guidance on company building, partnerships, and financing, and advises the company’s neuro-metabolic and psychiatric programs.